“We are delighted that Dr. Bosserman has accepted this opportunity to lead the JOP,” said ASCO President Bruce E. Johnson, MD, FASCO. “Her experience in oncology practice, health policy, administration, research, and editing give her a uniquely broad view that will enable her to continue the journal’s growth and will help keep oncology professionals up-to-date as they face new challenges and a rapidly evolving care delivery system.”

Dr. Bosserman will oversee the development of each issue of JOP, working with its team of associate editors and editorial board to develop and execute the journal’s editorial scope and vision. The JOP’s mission is to provide necessary information and insights to keep oncology professionals current on changes in practice, and provide compressed, expert opinion addressing common clinical problems.

“As the care landscape continues to change, oncology care professionals encounter many challenges in care delivery,” said Dr. Bosserman. “I am eager to take on this role and provide the JOP as a tool to guide conversation in areas including health services research, business and socioeconomics, ethics, and health policy with fresh, contemporary research and perspectives.”

Dr. Bosserman’s term will officially begin on January 1, 2019, following the 10-year term of John V. Cox, DO, FASCO. Over the past decade the visibility of the journal’s content has dramatically increased. The JOP is listed in multiple indexes including Medline and, beginning in 2018, the core collection of the Web of Science—resulting in the journal’s first impact factor. In 2015, the journal went from a bi-monthly to monthly publication, adding focused clinical content.

“I could not be happier with the knowledge that Dr. Bosserman will be my successor as editor of JOP,” said Dr. Cox. “Her remarkable enthusiasm, along with her experience and knowledge of oncology practice, will ensure that the journal excels.”

Dr. Bosserman has served as a medical oncologist and breast and women’s cancer specialist at City of Hope since 2014. She currently works on several value-based initiatives as well as telemedicine and remote second opinions as medical advisor to City of Hope’s Center for International Medicine. Before her practice joined City of Hope, Dr. Bosserman was a community medical oncologist with the Wilshire Oncology Medical Group for 24 years and its elected managing partner for 12 years. The group piloted work in electronic records in oncology practice to support value-based initiatives with managed care and medical home pilots while participating in clinical research trials with cooperative groups, UCLA, Sarah Cannon, and U.S. Oncology research networks. Dr. Bosserman also previously served as Chair of the Breast Committee and the Board of Directors of the California division of the American Cancer Society, as well as the Director of the Breast Health Program at the San Antonio Community Hospital, the Medical Director for California for U.S. Oncology, and as Chief Medical Officer for Cancer Centers of Excellence. 

Dr. Bosserman also brings a wealth of expertise in scientific journals, having served as an Editor of the Journal of Community and Supportive Oncology since 2004, and on the Editorial Advisory Board of Oncology from 1999 to 2017. Additionally, she has worked as an invited reviewer for JOP since 2013. She is passionate about bringing state of the art science and implementation methodologies to busy clinicians in ways that support rapid assimilation into daily practice.  

An ASCO member since 1990, she currently sits on the society’s Board of Directors, as well as its Provider Payment Reform Task Force and Clinical Pathways Task Force. She has also done extensive work in oncology medical home-based care and was a Clinical Instructor of Medicine at Harvard University and Stanford University School of Medicine.  

Dr. Bosserman received her undergraduate degree from University of California, Berkeley, in biochemistry with the highest honors and her medical degree from Stanford University School of Medicine. She completed both her internship and residency at Stanford University Hospital, followed by her oncology fellowship at the Dana-Farber Cancer Institute, Harvard Medical School, and Brigham and Women’s Hospital.